The emergence of YMDD mutants precedes biochemical flare by 19 weeks in lamivudine-treated chronic hepatitis B patients: an opportunity for therapy reevaluation

Given the loss of therapeutic efficacy associated with the development of resistance to lamivudine (LMV) and the availability of new alternative treatments for chronic hepatitis B patients, early detection of viral genotypic resistance could allow the clinician to consider therapy modification befor...

ver descrição completa

Detalhes bibliográficos
Autor principal: França,P.H.C. (author)
Outros Autores: Coelho,H.S.M. (author), Brandão,C.E. (author), Segadas,J.A. (author), Quintaes,R.F. (author), Carrilho,F.J. (author), Ono-Nita,S. (author), Mattos,A.A. (author), Tovo,C. (author), Gouvea,V.S. (author), Sablon,E. (author), Vanderborght,B.O.M. (author)
Formato: article
Idioma:eng
Publicado em: 2007
Assuntos:
Hepatitis B
Antiviral therapy
Lamivudine
Drug resistance
YMDD variants
Hepatitis B virus
Texto completo:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007001200003
País:Brasil
Oai:oai:scielo:S0100-879X2007001200003

Texto Completo

http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007001200003

Registros relacionados